Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT: Secukinumab in Thyroid Eye Disease
NCT04737330Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in thyroid eye disease (TED), sponsored by Novartis. Started Nov 2021; status: terminated.
02
Drugs
secukinumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT04737330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737330.